Skip to search formSkip to main contentSkip to account menu

Multicenter phase II study of the oral MEK inhibitor, CI-1040, in patients with advanced non-small-cell lung, breast, colon, and pancreatic cancer.

TLDR
CI-1040 was generally well tolerated but demonstrated insufficient antitumor activity to warrant further development in the four tumors tested, and PD 0325901, a second generation MEK inhibitor, has recently entered clinical development and, with significantly improved pharmacologic and pharmaceutical properties, it may better test the therapeutic potential of MEK inhibition in cancer.
View on PubMed (opens in a new tab)

Phase I and pharmacodynamic study of the oral MEK inhibitor CI-1040 in patients with advanced malignancies.

TLDR
Both target suppression and antitumor activity were demonstrated in this phase I study of CI-1040, a small-molecule inhibitor of the dual-specificity kinases MEK -1 and MEK2 in patients with advanced malignancy.
View on PubMed (opens in a new tab)

Intratumoral injection of Clostridium novyi-NT spores induces antitumor responses

TLDR
Clostridium novyi-NT targets aberrant tumor physiology and can produce a precise, robust, and reproducible antitumor response, and is shown to can precisely eradicate neoplastic tissues in selected patients.
View on Science (opens in a new tab)

First-in-Class ERK1/2 Inhibitor Ulixertinib (BVD-523) in Patients with MAPK Mutant Advanced Solid Tumors: Results of a Phase I Dose-Escalation and Expansion Study.

TLDR
The first-in-human dose-escalation study of an ERK1/2 inhibitor for the treatment of patients with advanced solid tumors is described, which has an acceptable safety profile with favorable pharmacokinetics and has shown early evidence of clinical activity in NRAS- and BRAF V600- and non-V600-mutant solid-tumor malignancies.
View on PubMed (opens in a new tab)

Phase I study of bryostatin 1 in patients with relapsed non-Hodgkin's lymphoma and chronic lymphocytic leukemia.

TLDR
This phase I study defined the maximum-tolerated dose (MTD), major toxicities, and possible antitumor activity of bryostatin 1, a macrocyclic lactone in patients with relapsed non-Hodgkin's lymphoma and chronic lymphocytic leukemia and recommended phase II dose of 120 microg/m2 (40 microg-m2/d for 3 days).
View on PubMed (opens in a new tab)

Tumor lysis syndrome in small cell carcinoma and other solid tumors.

View on PubMed (opens in a new tab)

Phase II trial of intravenous CI-1042 in patients with metastatic colorectal cancer.

TLDR
In this phase II study, intravenous CI-1042 was administered safely to patients with advanced colorectal cancer and toxicity was manageable, consisting primarily of flu-like symptoms.
View on PubMed (opens in a new tab)

Phase II trial of bryostatin 1 in patients with relapsed low-grade non-Hodgkin's lymphoma and chronic lymphocytic leukemia.

TLDR
Phenotypic analysis by flow cytometric analysis on pre- and post-bryostatin 1-treated peripheral blood lymphocytes revealed up-regulation in the coexpression of CD11c/ CD22 on CD20+ B cells in two of four CLL patients studied, which is consistent with in vitro findings of differentiation of CLL cells to a hairy cell phenotype.
View on PubMed (opens in a new tab)

A comparative structural characterization of the human NSCL-1 and NSCL-2 genes. Two basic helix-loop-helix genes expressed in the developing nervous system.

View on PubMed (opens in a new tab)

A phase 1–2 clinical study of a second generation oral MEK inhibitor, PD 0325901 in patients with advanced cancer

3011 Background: Oral PD 0325901 is a potent inhibitor of the dual-specificity kinases, MEK1/2 (MAPK/ERK/Kinase), thereby preventing phosphorylation and subsequent activation of mitogen-activated p...
View via Publisher (opens in a new tab)
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)